Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.
Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.